Cross-species genomic and epigenomic landscape of retinoblastoma

Claudia A. Benavente, Justina Dolorita McEvoy, David Finkelstein, Lei Wei, Guolian Kang, Yong Dong Wang, Geoffrey Neale, Ragsdale Susan Ragsdale, Virginia Valentine, Armita Bahrami, Jamshid Temirov, Stanley Pounds, Jinghui Zhang, Michael A. Dyer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs. Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer.

Original languageEnglish (US)
Pages (from-to)844-859
Number of pages16
JournalOncotarget
Volume4
Issue number6
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Retinoblastoma
Epigenomics
Neoplasms
Retinal Neoplasms
Molecular Targeted Therapy
Translational Medical Research
Gene Silencing
Aneuploidy
Retina
Carcinogenesis
Nucleotides
Therapeutics

Keywords

  • Epigenetics
  • RB1
  • Retinoblastoma

ASJC Scopus subject areas

  • Oncology

Cite this

Benavente, C. A., McEvoy, J. D., Finkelstein, D., Wei, L., Kang, G., Wang, Y. D., ... Dyer, M. A. (2013). Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget, 4(6), 844-859.

Cross-species genomic and epigenomic landscape of retinoblastoma. / Benavente, Claudia A.; McEvoy, Justina Dolorita; Finkelstein, David; Wei, Lei; Kang, Guolian; Wang, Yong Dong; Neale, Geoffrey; Susan Ragsdale, Ragsdale; Valentine, Virginia; Bahrami, Armita; Temirov, Jamshid; Pounds, Stanley; Zhang, Jinghui; Dyer, Michael A.

In: Oncotarget, Vol. 4, No. 6, 06.2013, p. 844-859.

Research output: Contribution to journalArticle

Benavente, CA, McEvoy, JD, Finkelstein, D, Wei, L, Kang, G, Wang, YD, Neale, G, Susan Ragsdale, R, Valentine, V, Bahrami, A, Temirov, J, Pounds, S, Zhang, J & Dyer, MA 2013, 'Cross-species genomic and epigenomic landscape of retinoblastoma', Oncotarget, vol. 4, no. 6, pp. 844-859.
Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, Wang YD et al. Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget. 2013 Jun;4(6):844-859.
Benavente, Claudia A. ; McEvoy, Justina Dolorita ; Finkelstein, David ; Wei, Lei ; Kang, Guolian ; Wang, Yong Dong ; Neale, Geoffrey ; Susan Ragsdale, Ragsdale ; Valentine, Virginia ; Bahrami, Armita ; Temirov, Jamshid ; Pounds, Stanley ; Zhang, Jinghui ; Dyer, Michael A. / Cross-species genomic and epigenomic landscape of retinoblastoma. In: Oncotarget. 2013 ; Vol. 4, No. 6. pp. 844-859.
@article{292f360958cf47c9b82f37ab7012f8e3,
title = "Cross-species genomic and epigenomic landscape of retinoblastoma",
abstract = "Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs. Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer.",
keywords = "Epigenetics, RB1, Retinoblastoma",
author = "Benavente, {Claudia A.} and McEvoy, {Justina Dolorita} and David Finkelstein and Lei Wei and Guolian Kang and Wang, {Yong Dong} and Geoffrey Neale and {Susan Ragsdale}, Ragsdale and Virginia Valentine and Armita Bahrami and Jamshid Temirov and Stanley Pounds and Jinghui Zhang and Dyer, {Michael A.}",
year = "2013",
month = "6",
language = "English (US)",
volume = "4",
pages = "844--859",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Cross-species genomic and epigenomic landscape of retinoblastoma

AU - Benavente, Claudia A.

AU - McEvoy, Justina Dolorita

AU - Finkelstein, David

AU - Wei, Lei

AU - Kang, Guolian

AU - Wang, Yong Dong

AU - Neale, Geoffrey

AU - Susan Ragsdale, Ragsdale

AU - Valentine, Virginia

AU - Bahrami, Armita

AU - Temirov, Jamshid

AU - Pounds, Stanley

AU - Zhang, Jinghui

AU - Dyer, Michael A.

PY - 2013/6

Y1 - 2013/6

N2 - Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs. Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer.

AB - Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs. Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer.

KW - Epigenetics

KW - RB1

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=84880830430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880830430&partnerID=8YFLogxK

M3 - Article

C2 - 23765217

AN - SCOPUS:84880830430

VL - 4

SP - 844

EP - 859

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -